Clinical trials: Phase I
Healthy
Effect of Ketoconazole on Biliary Excretion of AZD0837
This is an explorative study and the scientific question to be investigated is if the biliary excretion of AZD0837 and its metabolites AR-H069927XX and AR-H067637XX are affected by co-administration with ketoconazole
- Trial name
- NCT00812344
- Testing
- AZD0837, Ketoconazole
- Where
- Sweden
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Japanese Healthy Male Adult Volunteers
E2022 Patch Formulation Single Dose Phase I Study
The purpose of this study is to evaluate the pharmacokinetics of a single dose of E2022 in healthy Japanese male volunteers.
- Trial name
- NCT01253434
- Testing
- E2022
- Where
- Japan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Eisai Co., Ltd.
Healthy Subjects, Plasma Concentration of Mirabegron
A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects
The purpose of this study is to evaluate safety and absorption, distribution and elimination of mirabegron after oral administration to Chinese subjects.
- Trial name
- NCT01747564
- Testing
- YM178 (mirabegron)
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Macular Degeneration, Retinal Vein Occlusion
Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders
The use of intravitreal injections of corticosteroid (triamcinolone acetonide) appears to be a promising treatment for a variety of ocular diseases associated with inflammation.
- Conditions
- Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
- Trial name
- NCT00101764
- Testing
- Triamcinolone Acetonide
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Eye Institute (NEI)
Bioavailability
Study on Sapropterin Dihydrochloride Oral Suspension in Healthy Subjects
This is a single center, Phase 1, randomized, open-label, single-dose, 4 treatment, 4-period, 4-sequence, crossover study designed to compare the pharmacokinetics (PK) of sapropterin from the Test and Reference products, and to…
- Trial name
- NCT06481709
- Testing
- RLF-OD032, Kuvan
- Where
- Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- APR Applied Pharma Research s.a.
Urinary Bladder Cancer, Melanoma
MAGE-A4ᶜ¹º³²T for Multi-Tumor
This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung…
- Conditions
- Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT03132922
- Testing
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
- Where
- 11 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- USWM CT, LLC
Non-Small Cell Lung Cancer (NSCLC)
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
This research study is evaluating two drugs, alectinib and bevacizumab, as possible treatments for Advanced Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT02521051
- Testing
- Alectinib, Bevacizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
Bladder Cancer, Non Muscle Invasive
Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
The purpose of this study is to determine the safety and tolerability of intravesical BH011 in patients with high-risk non-muscle invasive bladder cancer（NMIBC） after Bacillus Calmette-Guerin（BCG） failure and to assess the…
- Trial name
- NCT06732531
- Testing
- BH011
- Where
- 6 sites in China
- Volunteers
- 48 people
- Sponsor
- Zhuhai Beihai Biotech Co., Ltd
Frailty in Older Adults
Safety and Tolerability Study of Mesenchymal Stem Cells, HeXell-2020, in Elderly Subjects With Mild to Moderate Frailty Syndrome
This is a phase I study to investigate the safety, and Tolerability of HeXell-2020 in Elderly Subjects with Mild to Moderate Frailty Syndrome.
- Trial name
- NCT07144072
- Testing
- HeXell-2020
- Volunteers
- 12 people
- Sponsor
- Hexun Biosciences Co., LTD.
Posttraumatic Stress Disorder
MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD
The goal of this clinical trial is to learn if cognitive-behavioral conjoint therapy (CBCT) in combination with MDMA-assisted therapy is safe and effective in people with chronic PTSD and their partners.
- Trial name
- NCT02876172
- Testing
- MDMA, CBCT, Therapy
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Resilient Pharmaceuticals
Neoplasms
Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer
The primary purpose of this study is to identify a dose of Liposome Entrapped c-raf Antisense Oligonucleotide Easy-to-Use (LErafAON-ETU) which maximizes potential benefits of the compound to patients with advanced cancer, without…
- Trial name
- NCT00100672
- Testing
- LErafAON-ETU
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- INSYS Therapeutics Inc
Advanced Malignancies
A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors
The purpose of this study is to evaluate the safety and tolerability of SHR-1501 in combination with SHR-1316 in patients with advanced malignancies and to provide a recommended dose (RP2D) for subsequent clinical studies.
- Trial name
- NCT03995472
- Testing
- SHR-1501, SHR-1316
- Where
- 5 sites in Australia, China
- Volunteers
- 14 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy
Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 113608 in Healthy Male Volunteers
The objective of the current trial is to evaluate safety, tolerability and pharmacokinetics of multiple rising doses of BI 113608 in healthy male volunteers
- Trial name
- NCT01681277
- Testing
- BI 113608 PIB bid, BI 113608 PIB qd
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Epilepsy
A Phase I Clinical Trial of UX-GIP001 in the Treatment of Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
This is a phase I study (Protocol: UX-GIP001-102) investigating UX-GIP001 Injection, a novel cell therapy product consisting of human GABAergic interneuron progenitor cells (GIP), for treating adult patients with drug-resistant…
- Trial name
- NCT07572812
- Testing
- UX-GIP001
- Where
- 3 sites in China
- Volunteers
- 12 people
- Sponsor
- Shanghai UniXell Biotechnology Co., Ltd
Breast Cancer
Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, methotrexate, fluorouracil, and epirubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT01031030
- Testing
- cyclophosphamide, epirubicin hydrochloride, fluorouracil
- Volunteers
- 800 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Non-Hodgkin's Lymphoma
Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma
This is a Phase I trial to look at safety and how a patient's body will tolerate the treatment at different dosages.
- Trial name
- NCT00285428
- Testing
- hA20-humanized anti-CD20 antibody
- Where
- 3 sites in United States
- Volunteers
- 82 people
- Sponsor
- Gilead Sciences
Acute Myeloid Leukemia (AML)
Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug UniCAR02-T-CD123 in patients with hematologic and…
- Trial name
- NCT04230265
- Testing
- Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), TM123 (IMP)
- Where
- 10 sites in Germany, Netherlands
- Volunteers
- 32 people
- Sponsor
- AvenCell Europe GmbH
Non-small Cell Lung Cancer
Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC
Pemetrexed is an FDA-approved treatment for advanced lung cancer but the response rate is still very low. Bortezomib is currently approved to treat myeloma in patients who have already been treated.
- Trial name
- NCT00516100
- Testing
- bortezomib
- Where
- 4 sites in United States
- Volunteers
- 62 people
- Sponsor
- Aptium Oncology Research Network
Macular Degeneration
Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration
The primary objective of this study is to determine the safety \& efficacy of ranibizumab for the treatment of retinal angiomatous proliferation secondary to age related macular degeneration.
- Trial name
- NCT00395707
- Testing
- Lucentis, Ranibizumab, Ranibizumab (Lucentis)
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- The National Retina Institute
Acute Leukemia, Chronic Leukemia
Trial of AVN-944 in Patients With Advanced Hematologic Malignancies
The purpose of this study is to determine the safety and maximum tolerated dose, pharmacokinetics, and anti-neoplastic response of AVN-944 in patients with advanced hematologic malignancies.
- Conditions
- Acute Leukemia, Chronic Leukemia, Multiple Myeloma, Hodgkin's Lymphoma
- Trial name
- NCT00273936
- Testing
- AVN-944 capsules for oral administration
- Where
- 5 sites in United States
- Volunteers
- 72 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.